Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 30:12:87-95.
doi: 10.2147/BTT.S126854. eCollection 2018.

Focus on biosimilar etanercept - bioequivalence and interchangeability

Fabrizio Cantini  1 , Maurizio Benucci  2
Affiliations
Review

Focus on biosimilar etanercept - bioequivalence and interchangeability

Fabrizio Cantini et al. Biologics. .

Abstract

Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the management of rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis due to the considerably lower cost of these products and the consequent savings.

Aims: To review the pharmacodynamics, pharmacokinetics, efficacy, and safety of ETN biosimilars when employed as first-line therapy or after transition from re-ETN. Patients' acceptability was also addressed.

Evidence review: The available literature was reviewed through a search of PubMed database, and abstract books of the American College for Rheumatology and European League Against Rheumatism annual meetings. SB4, GP2015, and HD203 were licensed by the US, European and South Korea regulatory agencies after the bioequivalence to re-ETN was demonstrated through pharmacodynamic and pharmacokinetic studies, and randomized, head to head, controlled trials. Based on the evidence of efficacy and safety of SB4 and HD203 in RA, and of GP2015 in psoriasis, by the extrapolation principle, the three biosimilars were approved for all indications licensed for re-ETN, and the regulatory agencies introduced the interchangeability from the originator to the biosimilar. Extrapolation of indications, and particularly interchangeability raised relevant concerns among the rheumatologists due to the low level of evidence supporting the switching strategy (or transition). Rheumatologists' concerns are oriented toward the relevant number of biosimilar discontinuations after the transition ranging from 7%-17% over a short-term follow-up period. As resulted from two studies, at least 20%-30% of the patients claimed more exhaustive information on the switching procedure.

Conclusion: Based on the available evidence, re-ETN biosimilars may be a good option as first-line therapy, while further data are needed to definitively establish the efficacy, safety, and the economic reflexes of transitioning from re-ETN.

Keywords: GP205; HD203; SB4; biosimilars; interchangeability; rheumatic diseases.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. European Medicines Agency (EMA) Biosimilars in EU. Information guide for healthcare professionals. London: EMA; 2017. [Accessed August 1, 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC5....
    1. US Food and Drug Administration Biosimilars. [Accessed October 23, 2017]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDe-velop....
    1. US Food and Drug Administration Background information: Lists of licensed biological products with reference product exclusivity and bio-similarity or interchangeability evaluations (purple book) [Accessed October 23, 2017]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsare-Develop....
    1. Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology. 2017;56(Suppl 4):iv30–iv48. - PMC - PubMed
    1. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 2018;78(4):463–478. - PMC - PubMed